Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Jim SimonsRenaissance Technologies $286k93k shares TrimQ1 2026 $137k $3.07 $5.99 | |||||
Ken GriffinCitadel Advisors $-55.4K ExitQ1 2026 $55k -- $5.99 | |||||
Jim SimonsRenaissance Technologies $422k107.5k shares AddQ4 2025 $55k $3.93 $5.99 | |||||
Ken GriffinCitadel Advisors $-29.7K ExitQ2 2025 $30k -- $5.99 | |||||
News
globenewswire.comLIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growthglobenewswire.comJun 3
globenewswire.comLIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directorsglobenewswire.comJun 1
globenewswire.comLIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directorsglobenewswire.comJun 1
globenewswire.comLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Updateglobenewswire.comMay 14
globenewswire.comFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conferenceglobenewswire.comApr 13